annotations:
  0:
    partial: false
    structured:
      - object: adverse effects
        measure: number of patients
  1:
    partial: true
    structured:
      - object: peak expiratory flow
        time: last week of the 8-week treatment period
        measure: mean
        specifier: pre-dose (and pre-rescue), as assessed via asthma monitor (am2+)
  2:
    partial: true
    structured:
      - object: disease control
        measure: percentage of participants
        specifier: according to recist version 1.1 in participants with low ercc-1 levels
  3:
    partial: false
    structured:
      - object: bcva
        measure: change
        specifier: in non-treated contralateral eye
  4:
    partial: true
    structured:
      - object: forced expiratory volume (fev1)
        specifier: in one second
        measure: mean change from baseline
        time: 2 hours post-dose
  5:
    partial: true
    structured:
      - object: asthma symptom score
        time: night time 
  6:
    partial: false
    structured:
      - object: enclomiphene pharmacokinetic parameters
        time: week 6 - tmax
  7:
    partial: false
    structured:
      - object: observed serum
        measure: maximum concentration (cmax)
        specifier: after administration of tba7371
  8:
    partial: false
    structured:
      - object: subject compliance with iti treatment regimen
        specifier: with iti treatment regimen
  9:
    partial: false
    structured:
      - object: phes
        time: week 26
        specifier: from pre-vancomycin
  10:
    partial: false
    structured:
      - object: pba of napba
        measure: cmax
        specifier: in plasma
      - object: hpn-100
        measure: cmax
        specifier: in plasma
  11:
    partial: true
    structured:
      - measure: number of patients
        object: adverse events # safety in fact
  12:
    partial: false
    structured:
      - object: Quality of life
        measure: change in mean
        specifier: measured with the veines qol/sym questionnaire
  13:
    partial: false
    structured:
      - object: promis measures-anger
  14:
    partial: false
    structured:
      - object: auct
        specifier: dose-normalized
        time: day 1
  15:
    partial: false
    structured:
      - object: patient satisfaction
        specifier: deflation mechanism
  16:
    partial: false
    structured:
      - object: preferred brand smoke intake
        specifier: co # carbon oxide
  17:
    partial: false
    structured:
      - object: severe cae # clinical adverse event
        specifier: when albuterol use increased
        time: prior to the peak
        measure: Number of days
  18:
    partial: false
    structured:
      - object: pain relief
        time: at 2 hours
        specifier: during the third migraine attack period
  19:
    partial: true
    structured:
      - object: attachment level
        specifier: using a williams periodontal probe
  20:
    partial: false
    structured:
      - object: cognitive function
        specifier: hopkins verbal learning test
        measure: total recall score
  21:
    partial: false
    structured:
      - object: adenoma detection rate
        specifier: colon ascendens
  22:
    partial: false
    structured:
      - object: area under the curve
        specifier: auc3.9-ig
        range: ig ≤3.9 mmol/l [70 mg/dl]
  23:
    partial: true
    structured:
      - object: significant laboratory values
        measure: number of participants
  24:
    partial: false
    structured:
      - object: visual acuity
        range: at least 0.30 logmar
        specifier: gaining in binocular distance-corrected (without near correction)
        measure: percentage of participants
        time: from baseline at month 3
  25:
    partial: true
    structured:
      - object: palatability
        specifier: trametinib oral solution
  26:
    partial: false
    structured:
      - object: patients with a stillbirth
        specifier: after rpl
  27:
    partial: false
    structured:
      - object: insulin dose
        specifier: total bolus
        unit: units/kg/day
  28:
    partial: false
    structured:
      - object: Antiretroviral resistance 
        specifier: to gw873140 400 mg bid and other antiretroviral drugs
        measure: Number of participants
  29:
    partial: false
    structured:
      - object: Adverse effect
        measure: Number of participants
  30:
    partial: true
    structured:
      - measure: change in mean 
        object: self-confidence score
  31:
    partial: true # missing patients randomized at week 18
    structured:
      - measure: change from baseline
        object: vitality
        specifier: short form 36-item health survey domain
        time: at week 34
  32:
    partial: false
    structured:
      - object: pain
        specifier: with needling
  33:
    partial: true
    structured:
      - object: concentration of rivaroxaban 
        specifier: in plasma
        time: day 1
  34:
    partial: false
    structured:
      - object: plasma concentration time profiles
        specifier: by treatment group
        time: in expansion phase
  35:
    partial: true  # at Least 10mm
    structured:
      - object: physically active
        measure: number of participants
      - object: not physically active
        measure: number of participants
  36:
    partial: false
    structured:
      - object: absolute fbf
        measure: change
        specifier: in response to l-nmma in participants treated with darbepoetin alfa
        time: day 42 vs day 1
  37:
    partial: false  # Visit 4
    structured:
      - object: pef
        measure: change from baseline
        specifier: averaged over the 12-week treatment period
        time: in daily morning
  38:
    partial: true  
    structured:
      - object: score of facit-fatigue scale
  39:
    partial: false 
    structured:
      - object: bowel length
  40:
    partial: false 
    structured:
      - object: evr
        measure: number of participants
        specifier: by selected chronic hcv genotypes (stage 1)
  41:
    partial: false 
    structured:
      - measure: number of participants
        object: dose-limiting toxicities (dlts)
        time: in first 2 cycles of portion a
  42:
    partial: false  
    structured:
      - object: medically significant conditions (mscs)
        measure: number of subjects
        time: from day 0 up to month 7
  43:
    partial: false
    structured:
      - object: resolution of dactylitis
        measure: percentage of participants
        specifier: among participants with dactylitis at baseline
        time: weeks 52
      - object: resolution of dactylitis
        measure: percentage of participants
        specifier: among participants with dactylitis at baseline
        time: weeks 76
      - object: resolution of dactylitis
        measure: percentage of participants
        specifier: among participants with dactylitis at baseline
        time: weeks 100
  44:
    partial: false
    structured:
      - object: depressive symptoms
        measure: level
        specifier: per edinburgh postnatal depression scale (epds)
  45:
    partial: false 
    structured:
      - object: event free survival (efs)
        measure: median
  46:
    partial: false 
    structured:
      - measure: change
        object: smpg profiles per time point
        time: from baseline to month 6
        specifier: in 8--point
  47:
    partial: false 
    structured:
      - object: hematology laboratory parameters
        specifier: worst changes
        measure: number of participants
        time: during the in the placebo controlled period
  48:
    partial: true
    structured:
      - object: pcl-5 score
        specifier: ptsd symptoms
        measure: change
  49:
    partial: false
    structured:
      - measure: change from baseline
        object: concentration of gag
        specifier: in urine
        time: at week 48
  50:
    partial: false
    structured:
      - object: toxicity
        specifier: assessed using national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (v5)
  51:
    partial: false
    structured:
      - object: insulin doses
        measure: average daily
  52:
    partial: false
    structured:
      - object: objective response - phase 1
        measure: percentage of participants
  53:
    partial: false
    structured:
      - object: renal deterioration
        measure: percentage of participants
        time: at any post baseline visit through day 14
  54:
    partial: false
    structured:
      - object: quality of life
        specifier: measured by the breast-q questionnaire
  55:
    partial: true # non-serotype specific?
    structured:
      - object: minor response rate
  56:
    partial: false
    structured:
      - object: evaluation of biomarkers
  57:
    partial: false
    structured:
      - object: reduction in tumour volume
        measure: number of patients
        time: 15 Minutes Post-treatment
        range: at least a 20%
        time: from baseline volume (visit 1) to week 12 (visit 3) 
      - object: reduction in tumour volume
        measure: number of patients
        time: 15 Minutes Post-treatment
        range: at least a 20%
        time: from baseline volume (visit 1) to week 24 (visit 4)
  58:
    partial: false
    structured:
      - object: influenza vaccine coverage
        specifier: for all household contacts of newborns
        measure: percent
  59:
    partial: true
    structured:
      - object: incidence 
        specifier: of new tec
      - object: incidence 
        specifier: of major bleeding
  60:
    partial: false
    structured:
      - object: pulmonary exacerbation
        measure: time to first
        time: over the 26-week treatment period
  61:
    partial: false
    structured:
      - object: received concomitant non-cancer therapy
        measure: percentage of participants
  62:
    partial: false
    structured:
      - object: mean pain score
        measure: change from baseline
        time: daily
        specifier: pain rating scale (dprs)
  63:
    partial: false
    structured:
      - object: neck pain
        measure: average level
  64:
    partial: false
    structured:
      - measure: change from baseline 
        object: toxin immunoglobulin g levels 
        specifier: among seropositive participants who received tdap to those who received td
  65:
    partial: false
    structured:
      - object: estimated post-bronchodilator slow vital capacity (svc)
        time: at month 48
  66:
    partial: false
    structured:
      - object: terminal half-life (t1/2) 
        specifier: of danirixin for part 2
  67:
    partial: false
    structured:
      - measure: number of patients
        object: transmitted light intensity
        specifier: to gastric wall thickness
  68:
    partial: false
    structured:
      - object: lens fit
        measure: horizontal centration
        specifier: hema-copolymer
      - object: lens fit
        measure: horizontal centration
        specifier: etafilcon a
  69:
    partial: true
    structured:
      - object: objective response rate (or) 
        specifier: where or=cr+pr
  70:
    partial: false
    structured:
      - object: ambulation
        measure: time of first
  71:
    partial: true
    structured:
      - object: terminal phase half-life (t1/2)
        specifier: gsk3358699
  72:
    partial: false
    structured:
      - object: nbs
        time: at week 40
        measure: change from baseline
  73:
    partial: false
    structured:
      - object: efficacy
        specifier: all-cause mortality
  74:
    partial: false
    structured:
      - object: spga 
        time: from baseline at week 24 
        specifier: by baseline bsa involvement subgroups
        range: at least a 2 grade improvement
        measure: percentage of participants
  75:
    partial: false
    structured:
      - object: experienced adverse events (aes)
        measure: number of participants
      - object: serious adverse events
        measure: number of participants
      - object: deaths
        measure: number of participants
  76:
    partial: false
    structured:
      - object: success rate
  77:
    partial: true # category
    structured:
      - object: used concomitant medications and rescue medications
        measure: number of participants
  78:
    partial: false
    structured:
      - measure: number of participants
        object: hospitalization for heart failure (hhf) 
        time: until 30 days after initial hospital discharge
  79:
    partial: false 
    structured:
      - object: vital signs data meeting categorical criteria 
        specifier: absolute values
        measure: number of participants
  80:
    partial: false
    structured:
      - object: percent radioactivity recovered 
        specifier: for each metabolite in duodenal bile 
        time: following a single dose of [14c]-gsk1278863 50 µg iv infusion
  81:
    partial: false
    structured:
      - object: days
        specifier: with < 8 micturitions
        measure: number
        time: weeks 4
      - object: days
        specifier: with < 8 micturitions
        measure: number
        time: weeks 8
      - object: days
        specifier: with < 8 micturitions
        measure: number
        time: weeks 12
      - object: days
        specifier: with < 8 micturitions
        measure: number
        time: eot
  82:
    partial: false
    structured:
      - object: methotrexate clearance 
        specifier: in induction cycle 2
  83:
    partial: false
    structured:
      - measure: percentage of participants
        object: psoriasis area severity index (pasi) score (pasi 100) 
        specifier: achieving 100% improvement
        time: at week 16
  84:
    partial: false
    structured:
      - object: montgomery åsberg depression rating scale (madrs) total score
        specifier: through phase 3
        measure: mean baseline
      - object: montgomery åsberg depression rating scale (madrs) total score
        specifier: through phase 3
        measure: adjusted mean change
  85:
    partial: false
    structured:
      - object: duration of remission
        specifier: following cr (dor) in tp53 wt population
  86:
    partial: false
    structured:
      - object: resource utilization dementia-lite (rud - lite) scale
        time: week 104
        measure: change from baseline
  87:
    partial: false
    structured:
      - object: pharmacological interventions 
        specifier: for the management of the cognitive impairment in the subgroups of the intervention arm with and without additional inputs from informants
        measure: number of participants 
  88:
    partial: true
    structured:
      - object: am, pre-dose, instantaneous total nasal symptom (itnss) scores # could be split
        time: over the entire treatment period
        measure: mean change from baseline
  89:
    partial: false
    structured:
      - object: terminal elimination half life
  90:
    partial: false
    structured:
      - object: treatment-emergent adverse events (teaes)
        measure: number of participants
      - object: treatment-emergent serious adverse events (tesaes)
        measure: number of participants
  91:
    partial: false
    structured:
      - object: area under plasma concentration 
  92:
    partial: false
    structured:
      - object: antibody response to mumps
        specifier: for subjects who had previously received m-m-r ii + varivax - geometric mean titer
  93:
    partial: false
    structured:
      - object: operator assessment
  94:
    partial: false
    structured:
      - object: electrocardiogram (ecg) values
        range: outside range of potential clinical importance
        measure: number of participants
  95:
    partial: false
    structured:
      - object: composite autonomic symptom score (compass)
  96:
    partial: false
    structured:
      - measure: percentage of patients 
        object: crohn's disease activity index (cdai) response 
        specifier: defined as a decrease of at least 100 points in cdai score from baseline
        time: at week 10
  97:
    partial: false
    structured:
      - measure: percentage of participants
        object: score for overall pelvic pain 
        time: at week 52
        specifier: improvement, no change, or worsening from baseline 
  98:
    partial: true # range
    structured:
      - measure: the number of participants 
        object: seropositive 
        specifier: within each treatment arm who achieved a a/h1n1 strain-specific hai antibody titer ≥ 32 post dose
  99: # Effect of SPN-810 on Retrospective-Modified Overt Aggression Scale (R-MOAS) Remission Rate
    partial: false
    structured:
      - object: passed bladder trial
        specifier: number of participants 




    

  


      
      



      
    